Lomustine clinical trials
Lomustine is named as an intervention in 11 current clinical trials in our France, Switzerland, Canada, USA, Spain, Germany, Netherlands, Belgium, Italy, Israel, Denmark, Austria, Sweden, Australia, Norway, Portugal, Czechia and Mexico registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Children's Oncology Group (2). The most-studied condition is Glioblastoma.
Where Lomustine is approved
All regulators →Of the three regulators tracked here, the first to approve Lomustine was the US, on 4 Aug 1976.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Lomustine
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Lomustine works
All drug targets →- Acute myeloid leukemiaPhase 3
- Acute myeloid leukemia by FAB classificationPhase 3
- Anaplastic astrocytomaPhase 3
- Anaplastic oligoastrocytomaPhase 3
- Anaplastic oligodendrogliomaPhase 3
- Astrocytoma (excluding glioblastoma)Phase 3
- Diffuse intrinsic pontine gliomaPhase 3
- GlioblastomaPhase 3
- Grade III gliomaPhase 3
- Low grade gliomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL514, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7214, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Lomustine
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Lomustine
- ATC code
- L01AD02
- ChEMBL
- CHEMBL514
- DrugBank
- DB01206
- PubChem CID
- 3950
- CAS number
- 13010-47-4
- FDA UNII
- 7BRF0Z81KG
- Wikidata
- Q415378
- Wikipedia
- Lomustine
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Lomustine
11 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Lomustine
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Glioblastoma | 5 |
| Glioblastoma, IDH-wildtype | 2 |
| Glioblastoma Multiforme, Adult | 1 |
| Recurrent Glioblastoma | 1 |
| GBM | 1 |
| Cancer | 1 |
| Pancreatic Cancer | 1 |
| Sarcoma | 1 |
| Renal Cancer | 1 |
| Glioblastoma Multiforme | 1 |
| Glioblastoma Multiforme of Brain | 1 |
| First Progression of Glioblastoma | 1 |
| MGMT-Methylated Glioblastoma | 1 |
| Childhood Medulloblastoma | 1 |
| Gliosarcoma | 1 |
| Medulloblastoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Children's Oncology Group | 2 |
| CNS Pharmaceuticals, Inc | 1 |
| Philogen S.p.A | 1 |
| CarThera | 1 |
| Actuate Therapeutics Inc | 1 |
| Jasper Gerritsen | 1 |
| Global Coalition for Adaptive Research | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Vastra Gotaland Region | 1 |
| NRG Oncology | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Lomustine trials
How many clinical trials are testing Lomustine?
11 current trials in our France, Switzerland, Canada, USA, Spain, Germany, Netherlands, Belgium, Italy, Israel, Denmark, Austria, Sweden, Australia, Norway, Portugal, Czechia and Mexico registers name Lomustine (also registered as 1-Nitrosourea) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Lomustine trials recruiting patients?
Yes. 5 of the 11 trials are recruiting: 2 with sites in France, 3 with sites in Switzerland, 2 with sites in Canada, 1 with sites in Spain, 3 with sites in Germany, 2 with sites in Netherlands, 2 with sites in Belgium, 1 with sites in Italy, 1 with sites in Israel, 2 with sites in Denmark, 2 with sites in Austria, 1 with sites in Sweden, 1 with sites in Australia, 2 with sites in Norway and 1 with sites in Czechia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Lomustine clinical trials?
Children's Oncology Group (2), CNS Pharmaceuticals, Inc (1), Philogen S.p.A (1) and CarThera (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Lomustine works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lomustine works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lomustine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.